Epitalon vs Humanin.

Epitalon (also spelled Epithalon or Epithalone; sequence Ala-Glu-Asp-Gly, abbreviated AEDG) is a synthetic tetrapeptide developed in the 1980s by the Russian gerontologist Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It was designed to reproduce the proposed active fragment of Epithalamin, a crude peptide extract of the bovine pineal gland, and is classified as a short "peptide bioregulator." It is not a small-molecule drug or a hormone; the corresponding AEDG sequence was reported to be detectable in physiological pineal tissue only in 2017.

Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP), one of the first members of a class of small peptides encoded by short open reading frames within the mitochondrial genome rather than the nuclear genome. Its coding sequence sits inside the mitochondrial 16S ribosomal RNA region (MT-RNR2), and a near-identical nuclear-encoded form also exists. It was discovered in 2001 by Hashimoto and colleagues in Ikuo Nishimoto's lab at Keio University during a cDNA screen for factors that protected neurons from Alzheimer's-disease-related insults, and it is studied primarily as a cytoprotective and metabolic signaling peptide.

The most cited proposed mechanism is activation of telomerase: in cultured human somatic cells, Epitalon has been reported to induce telomerase reverse transcriptase expression, lengthen telomeres, and extend the number of cell divisions past normal replicative (Hayflick) limits. A second proposed mechanism is epigenetic/gene-regulatory: AEDG is a short, cell-penetrating peptide that is hypothesized to bind directly to specific DNA promoter regions and modulate transcription, with reported effects on melatonin-synthesis enzymes (e.g., AANAT), interleukin-2, and neuronal differentiation genes. It has also been described as modulating pineal melatonin output and as having antioxidant effects in animal and Drosophila models. Importantly, after roughly 25 years of research the authoritative 2025 review concludes the true mechanism of action remains unclear, and some findings (e.g., on melatonin secretion) directly conflict between studies.

Humanin acts both intracellularly and as a secreted, receptor-mediated factor. Intracellularly it binds and antagonizes the pro-apoptotic Bcl-2-family proteins BAX, tBID and BimEL, blocking their translocation to mitochondria and suppressing apoptosis. Extracellularly it signals through a tripartite cytokine-like receptor complex (CNTF receptor / WSX-1 / gp130) that activates STAT3, and also engages formyl-peptide receptors (FPRL1/FPR2). It modulates insulin/IGF-1 signaling, interacting with IGFBP-3 and enhancing AKT phosphorylation, and acts centrally in the hypothalamus as an insulin sensitizer; the engineered S14G analog (HNG) is far more potent than the native peptide in preclinical assays.

Most evidence is preclinical (cell culture, Drosophila, mice, and rats), where Epitalon and Epithalamin have shown telomere lengthening and antioxidant effects; in some rodent lifespan experiments from Khavinson's group, they also reduced tumor incidence and extended mean lifespan. Human data are far thinner and come almost entirely from the same Russian research network. The most-cited human report (Khavinson & Morozov, Neuro Endocrinol Lett 2003, PMID 14523363) describes a 6–8 year follow-up of 266 elderly subjects in which Epithalamin (the pineal extract, not synthetic Epitalon) and thymalin were associated with reduced mortality versus controls; a related 15-year follow-up was published in 2011 (PMID 22451889). There are also small open-label reports in retinitis pigmentosa and a circadian/melatonin study. These studies are open-label, often unblinded, frequently use the crude extract rather than the synthetic tetrapeptide, and have not been independently replicated by Western randomized controlled trials. The human-vs-preclinical gap is large and unresolved.

The strongest data are preclinical. In cell and rodent models, humanin and HNG reduce neuronal death from amyloid-beta and other insults, shrink infarct size in stroke models, improve glucose handling, and reduce age-related cognitive decline in mice (Yen et al., Scientific Reports 2018; Hashimoto et al., J Neurosci 2001). Human evidence is observational, not interventional: circulating humanin declines with age, is lower in conditions such as Alzheimer's disease and the mitochondrial disorder MELAS, and higher levels have been associated with better "cognitive age" and with longevity-enriched cohorts (long-lived offspring, centenarians). Critically, there are no published randomized controlled trials of exogenous humanin or HNG in humans, and no completed published Phase 1 safety trial, so therapeutic benefit in people remains unproven and the human-versus-animal gap is large.

No rigorous, modern toxicology package exists for Epitalon. The 2025 International Journal of Molecular Sciences review explicitly states that data on this peptide's short- and long-term toxicity, genotoxicity, carcinogenic potential, and drug interactions are missing, and that these would be required before it could be approved as a pharmaceutical ingredient outside Russia. A specific theoretical concern is that a telomerase-activating compound could in principle promote survival or proliferation of abnormal cells, so its long-term oncologic safety in humans is genuinely unknown. Material sold for "research" use is unregulated, with no assurance of identity, purity, sterility, or endotoxin control. There are essentially no controlled human safety trials by Western standards.

Because no controlled human trials of administered humanin or HNG have been completed and published, the human safety profile is essentially unknown, including immunogenicity, dosing tolerability, and long-term effects. As a STAT3-activating, anti-apoptotic and growth-signaling peptide, theoretical concerns include effects on cell survival and proliferation pathways, but these have not been characterized clinically. Material sold online as "humanin" is research-use-only chemical of unverified identity and purity, not a pharmaceutical product, adding contamination and mislabeling risks. No safety conclusions for human use can be drawn from the existing animal and cell data.

Epitalon/Epithalamin reached clinical use only in Russia and has never been approved by the FDA or EMA; it is not an approved drug or dietary supplement in the United States and is sold there only as a research-use-only chemical. It is not a WADA-prohibited substance by name, though peptide-based agents can fall under broader anti-doping categories.

Humanin and its analog HNG are not approved by the FDA, EMA, or any major regulator for any indication; they are investigational/research-use-only compounds with no completed published Phase 1 human trial. They are not established WADA-prohibited substances by name, but exogenous peptides with growth-factor-like signaling can fall under broad anti-doping categories, so status should not be assumed.